A Patient-Focused Solution for Enrolling Clinical Trials in Rare and Selective Cancer Indications: A Landscape of Haystacks and Needles

Drug Information Journal

Volumn 46, Issue 4, 2012, Pages 472-478

  Lynam, Eric B ^a   Leaw, Jiin ^a   Wiener, Matthew B ^a  

^a Pharmatech Oncology Inc   (United States)

Author keywords

cancer research; clinical trials; enrollment; Just In Time; research methods

Indexed keywords

TUMOR MARKER;

ACCURACY; ARTICLE; CANCER CENTER; CANCER INCIDENCE; CANCER PATIENT; CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; DATA ANALYSIS; GENOTYPE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; METHODOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHYSICIAN; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SOLUTION AND SOLUBILITY; UNITED STATES;

EID: 84873808759     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/0092861512443436     Document Type: Article

References (31)

1. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011:.
2. HowladerNNooneAMKrapchoM, eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2008/. Based on November 2010 SEER data submission. Posted to the SEER web site 2011.
3. Mariotto AB,Yabroff KR,Shao Y,Feuer EJ,Brown ML.Projections of the cost of cancer care in the United States: 2010-2020.J Nat Can Inst. 2011;103 (2): 117-128.
4. Schilsky RL,Allen J,Benner J,Sigal E,McClellan M.Commentary: tackling the challenges of developing targeted therapies for cancer.Oncologist. 2010;15 (5): 484-487.
5. Tejeda HA,Green SB,Trimble EL, et al.Representation of African Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials.J Natl Cancer Inst. 1996;88:812-816.
6. Lara PN,Paterniti DA,Chiechi C, et al.Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials.J Clin Oncol. 2005;23:9282-9289.
7. Brief summary of Harris Interactive Survey (2000) findings. Coalition of Cancer Cooperative Groups Publications. http://www.cancertrialshelp.org/CTHpdf/1226-9.pdf. Accessed April 3, 2012.
8. Friedman A,Cain DF.National Cancer Institute-sponsored cooperative clinical trials.Cancer. 1990;65 (suppl 10): 2376-2382.
9. Go RS,Frisby KA,Lee JA, et al.Clinical trial accrual among new cancer patients at a community based cancer center.Cancer. 2006;106:426-433.
10. Klabunde CN,Springer BC,Butler B,White MS,Atkins J.Factors influencing enrollment in clinical trials for cancer treatment.South Med J. 1999;92:1189-1193.
11. Comis RL,Colaizzi D,Miller JD.Cancer clinical trials (CCT) awareness and attitudes in cancer survivors (Ca surv).J Clin Oncol. 2006;24 (18S): 6061.
12. Dilts DM,Sandler AB.Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.J Clin Oncol. 2006;24:4545-4552.
13. English R,Lebovitz Y,Griffin RTransforming clinical research in the United States: challenges and opportunities: workshop summary. Washington, DC: National Academies Press; 2010:.
14. Handelsman D.Optimizing clinical research operations with business analytics.2011 SAS Global Forum Proceedings. 2011;:204.
15. Durivage HJ,Bridges KD.Clinical trial metrics: protocol performance and resource utilization from 14 cancer centers.J Clin Oncol. 2009;27 (15S): 6557.
16. Fleming R.Barriers to clinical trials. Part I: reimbursement problems.Cancer. 1994;74:2662-2665.
17. Report of the National Cancer Institute Clinical Trials Program Review Group. Bethesda, MD: National Cancer Institute; 1997:.
18. Cohen GI.Cancer clinical trials; a primer for participation of community physicians.Am Soc Clin Oncol. 2002;:283-289.
19. Klabunde CN,Keating NL,Potosky AL, et al.A population-based assessment of specialty physician involvement in cancer clinical trials.J Natl Cancer Inst. 2011;103:1-14.
20. Cameron D,Cooper M,Haward B, et al.
21. Dilts DM,Sandler AB,Baker M, et al.Processes to activate phase III clinical trials in a cooperative oncology group: the case of cancer and leukemia group B.J Clin Oncol. 2006;24:4553-4557.
22. Markman M.The clinical trials cooperative group program: time for a painful reality check.Clin Oncol News. 2011;06 (05):
23. Cheng SK,Dietrich MS,Dilts DM.A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.Clin Cancer Res. 2010;16:5557-5563.
24. Stewart DJ,Kurzrock R.Cancer: the road to Amiens.J Clin Oncol. 2009;27 (3): 328-333.
25. Braiteh F,Kurkrock R.Uncommon tumors and exceptional therapies: paradox or paradigm?.Mol Cancer Ther. 2007;6:1175-1179.
26. Mikhail IS.
27. Wiener MB,Newman HM,Spradley EA.Revolutionizing oncology patient enrollment in clinical trials: Just-In-Time approach.J Clin Oncol. 2007;25 (18S): 6577.
28. Lynam EB.Clinical trials in the age of personalized cancer medicine: the evolution of a more efficient, patient focused clinical research system.DIA Annual Meeting Proceedings. 2010;:30691.
29. Smith BD,Smith GL,Hurria A,Hortobagyi GN,Buchholz TA.Future of cancer incidence in the United States: burdens upon an aging, changing nation.J Clin Oncol. 2009;27 (17): 2758-2765.
30. Patterson F,Gevorkian S.
31. Baker M.Protecting patient rights and regulatory compliance in a patient-directed clinical research.DIA Annual Meeting Proceedings. 2010;:30691.